ERBB2 and breast carcinoma: No miRNAs were found to be differentially expressed between the various molecular subtypes of breast cancer (estrogen receptor-positive, progesterone receptor-positive, and HER2 overexpressed) nor did any miRNA perform better as a biomarker for a certain molecular subtype.